Drug Delivery Innovation Center

The starting signal has been given for the Drug Delivery Innovation Center (DDIC) on September 1st, 2017! 

Founding Tier 1 members of the open consortium are the companies Bayer AG, LB Bohle GmbH, Merck KGaA* (all Germany) and UCB S.A (Belgium), together with the university partners TU Dortmund and HHU Düsseldorf. INVITE leads the consortium and builds the legal frame. 

Through partnership and close collaboration between academia, industry and public stakeholders we will build a world-class Center of Excellence in Drug Delivery Innovation based on established research platforms at the universities of Düsseldorf and Dortmund together with INVITE.

The DDIC will foster international, multi-disciplinary networks in the area of research to advance in pharmaceutical science in close collaboration with academia and pharmaceutical industry along the value chain. We also focus on increased fundamental process understanding as the foundation of advanced process control, modelling and prediction. DDIC not only stands for cutting-edge research in the fields of pharmaceutical and process technologies. To generate a highly skilled talent pool for our partners, the DDIC will establish a Master of “Industrial Pharmacy” and a unique PhD training program.

At DDIC we work on innovations and products for patients leading to better healthcare. The center will accelerate patient-centric innovations enabling the development of new technologies and advanced healthcare products and services in close cooperation with public stakeholders.

To provide you further information about the DDIC structure, membership levels and your benefits, you can find our DDIC Information Package in the Downloads section.

If you are interested to become a member of the DDIC please contact the Operational Director Dr. Werner Hoheisel: hoheisel[at]invite-research.com


Recent publications can be found here.



Research Areas

1. Low solubility / poor bioavailability of solid oral drugs

2. Drug delivery forms for special patient groups / personalized medicines (e. g. pediatric / geriatric)

3. Continuous processing

4. Fundamental process understanding / PAT / Scalability

5. Models for predicting biopharmaceutical properties

6. Drug formulations for biomolecules

7. Nanomedicines / nanotechnologies

DDIC Partners


*Known as "Merck KGaA, Darmstadt, Germany" in the United States of America and Canada.